Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
-
Published:2022-10
Issue:
Volume:52
Page:101590
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Brooks Benjamin RixORCID,
Berry James D.,
Ciepielewska Malgorzata,
Liu Ying,
Zambrano Gustavo Suarez,
Zhang Jeffrey,
Hagan Melissa
Reference30 articles.
1. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016;Mehta;Amyotroph Lateral Scler Frontotemporal Degener,2022
2. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015;Raymond;Amyotroph Lateral Scler Frontotemporal Degener,2019
3. Comparison of phenotypic characteristics and prognosis between black and white patients in a tertiary ALS clinic;Brand;Neurology,2021
4. Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009–2011 and survival characteristics through 2015;Punjani;Amyotroph Lateral Scler Frontotemporal Degener,2020
5. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial;Lancet Neurol,2017
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献